03 March 2008 London, UK: Antisoma plc (LSE: ASM; USOTC: ATSMY)
notifies the market that the Company's issued share capital consists
of 446,647,757 ordinary shares with voting rights. Antisoma does not
hold any ordinary shares in Treasury.
Therefore, the total number of voting rights in Antisoma is
The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Antisoma
under the FSA's Disclosure and Transparency Rules.
Raymond Spencer, CFO
Daniel Elger, Director of Communications
+44 (0)208 799 8200
Background on Antisoma
Headquartered in London, UK, Antisoma is a biopharmaceutical company
that develops novel products for the treatment of cancer. Antisoma
fills its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions. Its core activity is the preclinical and
clinical development of these drug candidates. Please visit
www.antisoma.com for further information.
---END OF MESSAGE---